Delcath’s Percutaneous Hepatic Perfusion (PHP) technology allows physicians to deliver significantly higher doses of existing chemotherapy drugs to the liver without exposing each patient’s entire body to the anti-cancer drugs.
FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
Interview with Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
MuGard: Potential Blockbuster for Oral Mucositis Prevention Market
Oral mucositis is a nearly inevitable complication for patients undergoing chemotherapy or radiation treatment for head or neck cancer.
